Personalized Therapy in Non-small Cell Lung Cancer
NCT01781988
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
128
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Carboplatin Adverse Reaction
Interventions
DRUG:
carboplatin, gemcitabine , pametrexed
Sponsor
Guangzhou Medical University
Collaborators
[object Object]